Cancers are usually treated by anticancer agents that are toxic for both normal and cancer cells, so these drugs have major side effects and they are not suitable and enough effective for cancer prevention. Solamargine, a steroidal alkaloid glycoside found in Solanum species such as Solanum nigrum, displayed several therapeutic activities. We aim to review the use of solamargine in experimental cancer studies. Articles published in biology journals between 1975 and 2017 were retrieved from PubMed, Scopus, and Web of Science using relevant keywords. The scientific papers mainly focusing on solamargine with therapeutic efficacies against cancers were identified and tabulated. In addition, the reliability of experimental findings was determined under “Risk of Bias” criteria. The author manually reviewed 33 articles; 27 articles were found concerning the anti‐cancer potential in cancer cells. Solamargine has been found to possess anticancer activities via its effect on a variety of biological pathways including cell survival pathways, tumor suppressor pathways, caspase activation pathway, mitochondrial pathways, death receptor pathways, protein kinase pathways, and signal pathways, which promote invasion/migration and multi drug resistance. Solamargine can be an anticancer agent candidate when complementary scientific evidences become available. Copyright © 2017 John Wiley & Sons, Ltd.

中文翻译：

---

Solamargine 的抗癌特性：系统评价

癌症通常使用对正常细胞和癌细胞都有毒的抗癌剂来治疗，因此这些药物具有很大的副作用，并且它们不适合用于预防癌症并且足够有效。Solamargine 是一种在茄属植物如 Solanum nigrum 中发现的甾体生物碱糖苷，具有多种治疗活性。我们的目标是审查 solamargine 在实验性癌症研究中的使用。使用相关关键词从 PubMed、Scopus 和 Web of Science 中检索 1975 年至 2017 年间发表在生物学期刊上的文章。主要关注具有抗癌疗效的茄碱的科学论文被确定并制成表格。此外，实验结果的可靠性是根据“偏差风险”标准确定的。作者人工审核33篇；发现27篇关于癌细胞抗癌潜力的文章。已发现 Solamargine 通过其对多种生物途径的影响而具有抗癌活性，包括细胞存活途径、肿瘤抑制途径、半胱天冬酶激活途径、线粒体途径、死亡受体途径、蛋白激酶途径和促进侵袭/迁移的信号途径和多重耐药性。当有补充的科学证据可用时，Solamargin 可以成为抗癌药物的候选者。版权所有 © 2017 John Wiley & Sons, Ltd. 死亡受体通路、蛋白激酶通路和信号通路，促进侵袭/迁移和多重耐药性。当有补充的科学证据可用时，Solamargin 可以成为抗癌药物的候选者。版权所有 © 2017 John Wiley & Sons, Ltd. 死亡受体通路、蛋白激酶通路和信号通路，促进侵袭/迁移和多重耐药性。当补充科学证据可用时，Solamargine 可以成为抗癌药物的候选者。版权所有 © 2017 John Wiley & Sons, Ltd.